Posts by: Diana Campelo Delgado

Diana Campelo Delgado

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.

February 4, 2021February 8, 2021

Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer

News

Note: This story was updated Feb. 8, 2021, to note that the ovarian cancer expansion group will include 40 participants, not 20. Sutro Biopharma‘s Phase 1 clinical trial has begun ... Read more

January 7, 2021January 7, 2021

$34M Funding Helps Speed Up New Class of Cancer Diagnostics

News

InterVenn Biosciences has raised $34 million to commercialize a new diagnostic tool for ovarian cancer, based on the identification of circulating proteins containing sugar molecules (glycoproteins). The company expects to ... Read more

December 8, 2020December 8, 2020

Phase 2 Trial Begins Testing VS-6766, Defactinib Combo in Low-grade Serous Ovarian Cancer

News

Verastem Oncology has started a Phase 2 clinical trial evaluating its inhibitors, VS-6766 and defactinib, for the treatment of people with recurrent low-grade serous ovarian cancer (LGSOC), the company announced. ... Read more